Can we Succeed in the Fight Against SARS-CoV-2 with its Emerging New Variants?
- 1 October 2022
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 28 (36), 2953-2964
- https://doi.org/10.2174/1381612828666220506142117
Abstract
In 2019, the whole world came together to confront a life-threatening virus named SARS-CoV-2, which causes COVID-19 illness. The virus infected the human host through the attachment to the ACE2 and CD147 receptors present in some human cells, resulting in cytokine storm and death. The new variants of the virus that caused concern, are Alpha, Beta, Gamma, Delta, and Epsilon based on the WHO label. However, Pango lineages designated them to B.1.1.7, B.1.351, P.1, B.1.617.2, and B.1.429. Variants may be progressively formed in one chronic COVID-19 patient and then transmitted to others. They show some differences in cellular and molecular mechanisms. Mutations in the receptor-binding domain (RBD) and N-terminal domain (NTD) lead to alterations of the host's physiological responses. They show significantly higher transmissibility rates and viral load while evading neutralizing antibodies at different rates. These effects are through mutations, deletion, and conformational alterations in the virus, resulting in the enhanced affinity of RBD to PD of ACE2 protein, virus entry, and spike conformational change. In the clinical laboratory, new variants may diagnose from other variants using specific primers for RBD or NTD. There are some controversial findings regarding the efficacy of the developed vaccines against the new variants. This research aimed to discuss the cellular and molecular mechanisms beyond COVID-19 pathogenesis, focusing on the new variants. We glanced at why the mutations and the ability to transmit the virus increase and how likely the available vaccines will be effective against these variants.Keywords
This publication has 89 references indexed in Scilit:
- Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and DiseaseInternational Journal of Peptides, 2012
- A Transmembrane Serine Protease Is Linked to the Severe Acute Respiratory Syndrome Coronavirus Receptor and Activates Virus EntryJournal of Virology, 2011
- Efficient Activation of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein by the Transmembrane Protease TMPRSS2Journal of Virology, 2010
- Genomic Characterization of Severe Acute Respiratory Syndrome-Related Coronavirus in European Bats and Classification of Coronaviruses Based on Partial RNA-Dependent RNA Polymerase Gene SequencesJournal of Virology, 2010
- Differential Downregulation of ACE2 by the Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus NL63Journal of Virology, 2010
- Ectodomain shedding of angiotensin converting enzyme 2 in human airway epitheliaAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2009
- Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sitesProceedings of the National Academy of Sciences of the United States of America, 2009
- Angiotensin‐converting enzyme 2 in the brain: properties and future directionsJournal of Neurochemistry, 2008
- Modulation of TNF-α-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-α production and facilitates viral entryProceedings of the National Academy of Sciences of the United States of America, 2008
- Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin systemAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2007